Treatment of acute myeloid leukemia with hypomethylating agents and 2-o, 3-o desulfated heparinoids
AssigneeCantex Pharmaceuticals, Inc.
InventorStephen Marcus
Life of this patent
Estimating the term…
Abstract
Methods are presented for treating cancers and hematopoietic stem cell disorders, comprising administering to a subject with a cancer or hematopoietic stem cell disorder who is receiving a treatment regimen, a heparin derivative capable of inhibiting, reducing, abrogating or otherwise interfering with the binding of CXCL12 to CXCR4, wherein the cancer or hematopoietic stem cell disorder is one in which interaction of CXCL12 with CXCR4 privileges the cancer or disordered HSCs against therapeutic intervention. In preferred embodiments, the heparin derivative is a substantially 2-O, 3-O-desulfated heparin derivative.
Claims105
A method of treating cancer, comprising:
- adjunctively administering to a patient receiving an antineoplastic treatment regimen a CXCL12-interacting heparinoid, in an amount and at a time effective to enhance effectiveness of the antineoplastic treatment regimen.
In a method for treating a cancer by administering to a subject in need thereof an antineoplastic treatment, the improvement comprising:
- administering to the subject a CXCL12-interacting heparinoid in an amount and at a time effective to enhance effectiveness of the antineoplastic treatment.
The method of claim 84, wherein the CXCL12-interacting heparinoid has an average molecular weight of about 11 kDa to about 13 kDa.
A method of treating a hematopoietic stem cell disorder, comprising:
- adjunctively administering to a subject with a hematopoietic stem cell disorder who is receiving a stem cell disorder treatment regimen, a CXCL12-interacting heparinoid, in an amount and at a time effective to enhance effectiveness of the treatment regimen.
The method of any of the preceding claims, wherein the treatment leads to reduced metastasis in the patient compared to those patients not treated with the CXCL12-interacting heparinoid.
The method of any of the preceding claims, wherein the treatment leads to increased survival in the patient compared to those patients not treated with the CXCL12-interacting heparinoid.
Dependencies are inferred from the claim text.